Apogee Therapeutics (APGE) Change in Cash (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Change in Cash data on file, last reported at $320.2 million in Q1 2026.

• Change in Cash for Q1 2026 came in at $320.2 million, up 1018.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $344.6 million (up 191.03% YoY), and the FY2025 annual result was -$10.5 million, down 144.88% from the prior year.
• Change in Cash improved to $320.2 million in Q1 2026 per APGE's latest filing, from $23.6 million in the prior quarter.
• Over five years, Change in Cash peaked at $367.1 million in Q1 2024 and troughed at -$188.5 million in Q3 2024.
• A 5-year average of $29.8 million and a median of -$2.4 million in 2022 frame the typical range for Change in Cash.
• On a YoY basis, Change in Cash climbed as much as 3577.7% in 2024 and fell as far as 995.41% in 2024.
• A 5-year view of Change in Cash shows it stood at $149.3 million in 2022, then tumbled by 146.65% to -$69.7 million in 2023, then jumped by 133.03% to $23.0 million in 2024, then gained by 2.72% to $23.6 million in 2025, then surged by 1254.97% to $320.2 million in 2026.
• Business Quant data shows APGE's Change in Cash at $320.2 million in Q1 2026, $23.6 million in Q4 2025, and -$16.6 million in Q3 2025.